Notably, the pan-RAS inhibitor RMC-977 has emerged as a promising therapeutic candidate for NF1-related tumors, showing efficacy in both in vitro and in vivo MPNST models [87]. This evidence concerns the gene NF1 and malignant peripheral nerve sheath tumor.